When PSA rises after surgery, PSMA PET/CT detects cancer missed by conventional imaging ...

Prostate cancer is the most common cancer diagnosis in men, accounting for 30% of male cancers in 2025, and is the second ...

Findings are in line with documented impacts on screening, diagnosis, and treatment ...

A new study reveals that cancer patients diagnosed during the early COVID-19 pandemic had worse short-term survival rates.

Though the findings are positive overall, survival increases since the mid-1990s are especially notable for more fatal ...

A real-world study found Erleada reduced the risk of death compared with Nubeqa in patients with metastatic ...

People who have received a cancer diagnosis are living longer than ever, according to a new report from the American Cancer Society (ACS). Decades of cancer research have led to more effective ...

Patients diagnosed with cancer in the U.S. during the first two years of the COVID-19 pandemic had significantly lower one-year cancer survival rates, leading to an estimated 17,390 more deaths than ...

The American Cancer Society released its annual statistics report that shows significant progress in cancer survival rates ...

The latest data point to improvements for many cancer types and a continued decline in overall cancer mortality.

A separate 2024 study in the Journal of the National Cancer Institute documented a dip in one-year survival for patients ...

A Registrational Phase 2 clinical trial has been initiated in Japan for patients with PSMA-positive metastatic castration-resistant prostate ...